ClinicalTrials.gg
RecruitingNCT07418736Updated Feb 18, 2026

A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Phase 2 interventional study of CM326 dose 1 and CM326 dose 2 in Chronic Obstructive Pulmonary Disease, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
318
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 108 open to participants now, 125 under way, 15 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Planned enrollment
99th of 286
318 · median 155
Started
2025
with 41 others
Phase 2
33 of 404
13 open now
Primary completion
2027-07
later than 71 of 124 live
Registered
372nd of 404
by date

Among the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 99th largest by planned enrollment of the 286 interventional ones that give a count, is one of 42 that started in 2025, is one of 33 in phase 2, reaches primary completion later than 71 of the 124 other live ones, and was the 372nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

108 of the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

102 more — sign in →

All 108 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to Severe Chronic Obstructive Pulmonary Disease.

The study consists of a screening period of up to 4 weeks, a randomized treatment period of 24 to 52 weeks, and a 12-week safety follow-up period.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand the study and voluntarily sign the form.
  2. Age ≥40 and ≤85 years old, male or female, at the time of signing the informed consent.
  3. weight ≥40 kg.
  4. Diagnosed with for at least 12 months.
  5. Post-bronchodilator /FVC ratio \<0.70 and post-bronchodilator FEV1 % predicted ≥20% and \<80%.
  6. Background therapy for 3 months prior to screening with a stable dose of medication for ≥1 month prior to screening.
  7. Exacerbation history of ≥2 moderate or ≥1 severe AECOPD within the year prior to screening.
  8. COPD assessment test (CAT) Total Score ≥10.
  9. Blood eosinophils ≥0.15×10\^9 /L at screening.
  10. Current smoking or a history of smoking ≥ 10 pack-years, or exposure to biomass smoke (including but not limited to biomass fuel, secondhand smoke, and the like) for ≥ 10 years.
  11. Voluntarily use highly effective from the time of signing the informed consent form until 3 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. A current diagnosis of asthma or history of asthma according to the Global Initiative for Asthma (GINA) guidelines(asthma alone or asthma as the primary diagnosis, including but not limited to asthma with )
  2. Subjects with significant pulmonary disease other than COPD (e.g., sarcoidosis, interstitial lung disease, primary pulmonary hypertension, bronchiectasis, Churg-Strauss Syndrome, active tuberculosis or non-tuberculous mycobacterial infection, etc.), in the opinion of the investigator. Or other conditions that could lead to elevated eosinophils.
  3. The presence of any severe and/or uncontrolled medical condition that in the judgment of the investigator would affect the evaluation of the drug, including but not limited to: severe neurological disease (eg, epilepsy, dementia, etc), history of severe mental disorder, major cardiovascular disease, diabetes mellitus poorly controlled by intensive treatment, interval prolongation(male >450 msec, female >470 msec), or persistent arrhythmia.
  4. History of .
  5. Previous history of known or suspected ; Or the presence of unusual frequent, recurrent, or prolonged infections, per investigator's judgment.
  6. Prior disease or inflammatory treatment with biologic agents/systemic immunosuppressive agents within 8 weeks or 5 half-lives (whichever is longer) prior to .
  7. Heart failure Class IV, uncontrolled Cor pulmonale as judged by the investigator or with evidence of right cardiac failure.
  8. Myocardial infarction, unstable angina, or stroke occurring within 6 months prior to signing the informed consent form (ICF).
  9. Parasitic infection diagnosed within 24 weeks prior to signing the informed consent form (ICF), which has not received standard treatment or is to standard treatment.
  10. Acute moderate or severe exacerbation of COPD from 4 weeks before signing consent to the time of randomization.
  11. Acute infection requiring systemic anti-infective therapy from 4 weeks before signing consent to the time of randomization.
  12. Major surgery within 8 weeks prior to consent or planned surgery requiring general anesthesia or hospitalization for > 1 day during the study period.
  13. History of or planned pneumonectomy or lung volume reduction surgery for COPD 12 months prior to screening.
  14. As judged by the investigator, long-term daily oxygen therapy for more than 15 hours per day due to medical necessity, or concurrent hypercapnia requiring the use of bilevel positive airway pressure (BiPAP) non-invasive ventilation.
  15. Patients who are participating in the acute phase of a pulmonary rehabilitation program, ie, who start rehabilitation \<4 weeks prior to screening (Note: patients in the maintenance phase of a rehabilitation program could be included).
  16. Patients who are treated with systemic (topical, ophthalmic, or intranasal corticosteroids are excluded) from 4 weeks before signing the informed consent to the date of randomization. Except for short-term (≤7 days) use of systemic glucocorticoids to prevent or treat non-autoimmune allergic diseases.
  17. Use of macrolide antibiotics (eg, azithromycin) unless stable >3 months prior to screening visit and maintain the treatment during the planned study period.
  18. Treatment with a PDE-4 inhibitor (roflumilast) (unless on stable treatment for ≥ 3 months with a plan to maintain stable treatment throughout the study period).。
  19. Anti-immunoglobulin E (IgE) therapy (omalizumab) within 130 days before consent or any other biologic therapy (including other anti-IL4R mAb, anti-IL5 mAb, anti-IL5R mAb, anti TSLP mAb, anti-IL33 mAb, anti-ST2 mAb) within 3 months or 5 half-lives before signing consent, whichever is longer.
  20. Have been enrolled in a clinical trial of any drug or medical device within 3 months before signing informed consent, or are within the follow-up period of a clinical study or the five half-lives of the trial drug (whichever is longer) before signing informed consent.
  21. Received immune globulin or blood products within 30 days before informed consent.
  22. Receipt of traditional Chinese medicines (TCMs), ethnic medicines, or natural medicines approved by the National Medical Products Administration (NMPA) for the indication of COPD treatment within 4 weeks prior to randomization.
  23. Receipt of live or attenuated vaccine within 3 months before consent signing or during the planned study period.
  24. Non-negative serological test result at screening, or Treponema pallidum infection requiring treatment.
  25. Subjects infected with chronic virus (HBV) or virus (HCV) must meet the following laboratory criteria during the screening period: a. HBsAg positive b. HBsAg negative , HBcAb positive, HBV DNA exceed the lower limit of quantitation (LLOQ) or 1000 copies/mL c. HCV antibody positive, HCV RNA exceed the LLOQ.
  26. At screening, (AST) or alanine aminotransferase (ALT) > 3 × (ULN), or serum creatinine (Cr) > 1.5 × ULN or serum creatinine > 1.5 × ULN.
  27. Females with a positive pregnancy test, pregnant females, or lactating females.
  28. Allergy or intolerance to components of CM326 injection or placebo or history of severe drug allergy or anaphylactic shock.
  29. History of drug abuse within 5 years before signing informed consent.
  30. \<70% compliance with usual COPD controller therapy in subjects during the screening phase.
  31. The investigator considers that there are any conditions that may prevent the subject from completing the study .
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
318 participants (estimated)

Study arms

  • Experimental
    CM326

    CM326 is dosed at two levels.

    Drug: CM326 dose 1 · Drug: CM326 dose 2

  • Placebo comparator
    Placebo

    placebo, subcutaneous (SC)

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbations

    Annualized rate of moderate or severe acute exacerbation of COPD (AECOPD) over the placebo-controlled treatment period.

    Time frame: week 24-52

Secondary outcomes

  1. Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1) at each evaluation time point

    FEV1 is the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Change from baseline in FEV1 taken before bronchodilator use will be reported.

    Time frame: week 16-24

  2. Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1) at each evaluation time point

    FEV1 is the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Change from baseline in FEV1 taken before bronchodilator use will be reported.

    Time frame: week 24-52

  3. Change from baseline in post-bronchodilator forced expiratory volume in 1 second (FEV1) at each evaluation time point

    FEV1 is the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Change from baseline in FEV1 taken after bronchodilator use will be reported.

    Time frame: week 24-52

  4. Change from baseline in Pre-bronchodilator Forced vital capacity (FVC) at each evaluation time point

    Change from baseline in forced vital capacity taken before bronchodilator use will be reported. FVC is measured by spirometer.

    Time frame: week 24-52

  5. Change from baseline in forced expiratory flow (FEF) at 25%-75% at each evaluation time point

    FEF is measured by spirometer.

    Time frame: week 24-52

  6. Time to the first onset of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbations

    Time to first moderate or severe AECOPD over the placebo-controlled treatment period.

    Time frame: week 24-52

  7. Time to the first onset of Severe Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbations

    Time to first severe AECOPD over the placebo-controlled treatment period.

    Time frame: week 24-52

  8. Annualized Rate of Severe Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbations

    Annualized rate of severe AECOPD over the placebo-controlled treatment period.

    Time frame: week 24-52

  9. Change from baseline in Saint (St.) George's Respiratory Questionnaire (SGRQ) Total Score at each evaluation time point

    The SGRQ is a 50-item questionnaire designed to measure and quantify health status in adult participants with chronic airflow limitation. A global score ranges from 0 to 100. Scores by dimension are calculated for 3 domains: Symptoms, Activity and Impacts (Psycho-social) as well as a total score. A lower score indicates better quality of life.

    Time frame: week 24-52

  10. Proportion of participants with an SGRQ Score improvement of ≥4 points from baseline at each evaluation time point.

    Proportion of participants achieving a clinically meaningful improvement from baseline in SGRQ total score (4-point score decrease) will be reported.

    Time frame: week 24-52

  11. Change from baseline in COPD assessment test (CAT) Total Score at each evaluation time point

    CAT is an 8-item PRO that measures the impact of COPD on the health status of patients with COPD. The CAT has a scoring range of 0-40 with higher scores indicative of greater COPD impact on health status.

    Time frame: week 24-52

  12. Proportion of participants with an CAT Score improvement of ≥2 points from baseline at each evaluation time point

    Proportion of participants achieving a clinically meaningful improvement from baseline in CAT total score (2-point score decrease) will be reported.

    Time frame: week 24-52

  13. Change from baseline in Evaluating Respiratory Symptoms (E-RS) total score at each evaluation time point

    The E-RS: COPD is administered as a part of the 14-item EXACT questionnaire and is completed on a daily basis. The 11-item E-RS:COPD assesses severity of respiratory symptoms overall and severity of individual symptoms such as breathlessness, cough and sputum, and chest symptoms The total score of E-RS:COPD ranges from 0 to 40, with higher values indicating more severe respiratory symptoms.

    Time frame: week 24-52

  14. Proportion of participants with an E-RS Score improvement of ≥2 points from baseline at each evaluation time point

    Proportion of participants achieving a clinically meaningful improvement from baseline in E-RS total score (2-point score decrease) will be reported.

    Time frame: week 24-52

  15. Incidence of Adverse events (AEs)/treatment-emergent adverse events (TEAEs) in

    The severity of adverse events is recorded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 6.0. The incidence of participants with adverse events (AE) will be calculated.

    Time frame: week 64

  16. Blood drug concentration Pharmacokinetic profile of CM326

    Time frame: week 64

  17. Pharmacodynamics profile of CM326 Change from baseline fractional exhaled nitric oxide (FeNO)

    Evaluate the changes from baseline in FeNO at each visit point.

    Time frame: week 64

  18. Change from baseline in peripheral blood eosinophil

    Evaluate the changes from baseline in blood eosinophil count at each visit point.

    Time frame: week 64

  19. Change from baseline in total serum IgE

    Evaluate the changes from baseline in total serum IgE at each visit point.

    Time frame: week 64

  20. Change from baseline in interleukin-5

    Evaluate the changes from baseline in blood serum IgE at each visit point

    Time frame: week 64

  21. Incidence of anti-drug antibodies (ADAs)

    Time frame: week 64

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2027, 18 months after the start.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 18 months is above that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 18, 2026
StartActual
Dec 18, 2025
Primary completionEst.
Jul 1, 2027
CompletionEst.
Oct 10, 2027
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07418736
Responsible party
Sponsor
First posted
Feb 18, 2026
Start date
Dec 18, 2025
Primary completion
Jul 1, 2027 (estimated)
Completion
Oct 10, 2027 (estimated)
Last update
Feb 18, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
031169085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocankitug

Start the discussion